Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation | Zendy

Tara Gomes | Zendy; Tonya Campbell | Zendy; Sophie A. Kitchen | Zendy; Ria Garg | Zendy; Nikki Bozinoff | Zendy; Siyu Men | Zendy; Mina Tadrous | Zendy; Charlotte Munro | Zendy; Tony Antoniou | Zendy; Dan Werb | Zendy; Jennifer Wyman | Zendy

Open Access

Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation

Author(s) -

Tara Gomes,

Tonya Campbell,

Sophie A. Kitchen,

Ria Garg,

Nikki Bozinoff,

Siyu Men,

Mina Tadrous,

Charlotte Munro,

Tony Antoniou,

Dan Werb,

Jennifer Wyman

Publication year - 2022

Publication title -

jama

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.688

H-Index - 680

eISSN - 1538-3598

pISSN - 0098-7484

DOI - 10.1001/jama.2022.1271

Subject(s) - medicine , discontinuation , opioid , opioid overdose , agonist , anesthesia , opioid epidemic , drug overdose , buprenorphine , pharmacology , emergency medicine , poison control , (+) naloxone , receptor

During the COVID-19 pandemic, modified guidance for opioid agonist therapy (OAT) allowed prescribers to increase the number of take-home doses to promote treatment retention. Whether this was associated with an increased risk of overdose is unclear.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research